[Skip To Content]
[Website of the National Cancer Institute's Technology Transfer Center. Partnering with Industry for Improved Public Health.]
  • Home
  • Collaborative Opportunities
  • Standard Forms and Agreements
  • Technology Transfer Training
  • Resources
  • Intellectual Property

Antisera to Detect Phosphorylated Phosphoinositide-Dependent Kinase 1 (PDK-

Background:
The National Institutes of Health, National Center for Complementary and Alternative Medicine, Diabetes Unit is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize phospho-specific PDK-1 antibody and insulin signaling.

Technology:
PDK-1 phosphorylates and activates a number of cellular kinases and plays a major role in insulin and growth factor signaling. PDK-1 also represents a promising drug target for a number of cancers. Autophosphorylation at Ser244 (mouse) or Ser241 (human) is critical for PDK-1 activity.

Available for licensing are polyclonal rabbit antisera that specifically detect mouse PDK-1 protein phosphorylated at Ser244. These antisera are also expected to be specific for the human PDK-1 protein phosphorylated at Ser241.

IP Status:
Research Tool

Value Proposition--Solution:
  • Tool for screening PDK-1 autophosphorylation inhibitors for cancer and other indications
  • Tool for studying insulin and growth factor signaling

Contact Information:
John D. Hewes, Ph.D., NCI Technology Transfer Center
Phone: 301-435-3121
E-mail: Hewesj@mail.nih.gov

Reference:  #580 CM

Posted 11/21/2007

This opportunity is also listed under the following categories:

E-MAIL SERVICE

TTC maintains an e-mail service to notify you of new Collaborative Opportunities. If you would like to receive these emails, please sign up below. If you'd like to unsubscribe you can use this form as well.

Page Last Updated: 12-17-2008